Status:
COMPLETED
Induction Treatment of Proliferative Lupus Nephritis With Leflunomide Combined With Prednisone
Lead Sponsor:
Peking University
Conditions:
Nephritis, Lupus
Eligibility:
All Genders
16+ years
Phase:
PHASE2
PHASE3
Brief Summary
lupus nephritis accounts for the most morbidity and mortality in patients with SLE. Glucocorticoids combined with cyclophosphamide (CYC) are effective for the treatment of patients with proliferative ...
Eligibility Criteria
Inclusion
- All patients were diagnosed as SLE according to the updated criteria of American College of Rheumatology in 1997, had a systemic lupus erythematosus disease activity index (SLEDAI)equal or greater than 8; had evident renal diseases and biopsy-documented diffuse proliferative or focal proliferative lupus nephritis, with or without coincident membranous nephropathy, and pathological activity index (AI)equal or greater than 4
Exclusion
- Patients who had received cyclophosphamide within the previous 3 months, cerebral lupus, severe infection, liver disease, pregnancy, and anticipated poor compliance with the protocol.
Key Trial Info
Start Date :
October 1 2002
Trial Type :
INTERVENTIONAL
End Date :
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT00268567
Start Date
October 1 2002
Last Update
December 22 2005
Active Locations (8)
Enter a location and click search to find clinical trials sorted by distance.
1
Renal Division, Peking University First Hospital
Beijing, China, 100034
2
Department of Nephrology, Kidney Center and key Lab of PLA, Chinese General Hospital of PLA
Beijing, China
3
Division of Nephrology, Nanfang Hospital, Southern Medical University
Guangzhou, China
4
Renal Division, the First Affiliated Hospital, Sun Yat-sen University
Guangzhou, China